PALO ALTO, Calif., Nov. 1, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin™, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.
The clinical trial is conducted by Shanghai's Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine. As previously reported, the interim analysis of the trial demonstrated that patients had a clinically meaningful reduction in pain and increase in mobility, with a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events were reported for the duration of the trial.
Full data analysis by FuDan Medical University Department of Biostatistics will be carried out in the next four to six weeks and the final report of the trial will be announced before the end of the year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Director of Corporate Communications, CBMG
+1 650 566 5064
|SOURCE Cellular Biomedicine Group|
Copyright©2012 PR Newswire.
All rights reserved